TOPIC: Zepatier - PBAC yes for GT1 but no for GT3

The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time. [which is a damn pity because Canada disagrees]

That is wonderful news for genotypes 4 and 6 including G1's but it seems so very unfair for those with G3. Where is the dislike tab?

Maybe it's possible that Zepatier could interfere with the PBAC's deal with Gilead and funding caps given that G3 is more prevelant here.